We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+12.8%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$237M
AUM Growth
-$4.18M
Cap. Flow
-$18.3M
Cap. Flow %
-7.71%
Top 10 Hldgs %
7.93%
Holding
416
New
61
Increased
247
Reduced
47
Closed
61

Sector Composition

Rank Sector Weight
1 Healthcare 30.46%
2 Real Estate 18.03%
3 Energy 13.68%
4 Materials 11.34%
5 Utilities 10.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BKCC
301
DELISTED
BlackRock Capital Investment Corporation
BKCC
$236K 0.1%
70,427
-1,944
-3% -$6.17K
TCRR
302
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$236K 0.1%
10,683
+192
+2% +$5.24K
VXRT
303
DELISTED
Vaxart
VXRT
$235K 0.1%
38,917
+678
+2% +$5.22K
RPTX
304
DELISTED
Repare Therapeutics
RPTX
$234K 0.1%
7,612
+143
+2% +$4.86K
APLT
305
DELISTED
Applied Therapeutics
APLT
$233K 0.1%
12,438
+222
+2% +$4.79K
FCRD
306
DELISTED
First Eagle Alternative Capital BDC, Inc. Common Stock
FCRD
$233K 0.1%
57,782
-4,088
-7% -$15.7K
SUNS
307
DELISTED
SLR Senior Investment Corp. Common Stock
SUNS
$228K 0.1%
15,519
+1,581
+11% +$23.7K
CVAC
308
DELISTED
CureVac
CVAC
$227K 0.1%
2,480
+43
+2% +$4.17K
PGEN icon
309
Precigen
PGEN
$1.94B
$224K 0.09%
32,527
+565
+2% +$4.78K
TPTX
310
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$224K 0.09%
2,366
+33
+1% +$3.92K
AGEN
311
Agenus
AGEN
$276M
$223K 0.09%
4,169
+73
+2% +$5.28K
CNST
312
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$222K 0.09%
9,500
+169
+2% +$5.12K
MRTX
313
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$219K 0.09%
1,278
+22
+2% +$4.36K
QURE icon
314
uniQure
QURE
$2.75B
$218K 0.09%
6,467
+113
+2% +$4.05K
ADCT icon
315
ADC Therapeutics
ADCT
$140M
$214K 0.09%
8,776
+160
+2% +$4.63K
AXSM icon
316
Axsome Therapeutics
AXSM
$11.7B
$213K 0.09%
3,758
+68
+2% +$4.78K
BDTX icon
317
Black Diamond Therapeutics
BDTX
$95.1M
$212K 0.09%
8,756
+153
+2% +$4.13K
ADVM
318
DELISTED
Adverum Biotechnologies
ADVM
$211K 0.09%
2,144
+38
+2% +$4.56K
ASND icon
319
Ascendis Pharma A/S
ASND
$16.5B
$211K 0.09%
1,641
+27
+2% +$4.1K
RYTM icon
320
Rhythm Pharmaceuticals
RYTM
$7.31B
$211K 0.09%
9,939
+167
+2% +$4.84K
REPL icon
321
Replimune Group
REPL
$454M
$210K 0.09%
6,887
+118
+2% +$4.42K
DNLI icon
322
Denali Therapeutics
DNLI
$3.79B
$208K 0.09%
3,644
+58
+2% +$3.88K
STOK icon
323
Stoke Therapeutics
STOK
$1.84B
$208K 0.09%
5,361
+97
+2% +$5.52K
ORIC icon
324
Oric Pharmaceuticals
ORIC
$1.17B
$206K 0.09%
8,394
+147
+2% +$4.64K
EDIT icon
325
Editas Medicine
EDIT
$399M
$205K 0.09%
4,884
+86
+2% +$4.9K

Similar funds

Virtus ETF Advisers's Q1 2021 Portfolio in Review

As of Q1 2021, Virtus ETF Advisers held 416 positions worth $237M, down 1.7% from $241M the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.

Virtus ETF Advisers withdrew a net $18.3M in Q1 2021, closing 61 positions and reducing 47 holdings. Its most notable exit was Ryman Hospitality Properties, an estimated $2.57M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 30% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Virtus ETF Advisers opened a new position in Pioneer Natural Resource Co. worth $1.99M.

  • Virtus ETF Advisers's largest Q1 2021 buy was Pioneer Natural Resource Co.: 12,538 shares worth $1.99M.
  • Virtus ETF Advisers added most to Oaktree Specialty Lending in Q1 2021, an estimated $216K increase.
  • Virtus ETF Advisers's biggest Q1 2021 reduction was Avient, cutting an estimated $916K.
  • Virtus ETF Advisers fully exited Ryman Hospitality Properties in Q1 2021, selling an estimated $2.57M.
  • Virtus ETF Advisers's ten largest holdings make up 7.9% of its $237M portfolio in Q1 2021.
  • Virtus ETF Advisers opened 61 new positions and closed 61 in Q1 2021.
  • Virtus ETF Advisers's portfolio value fell 1.7% quarter-over-quarter to $237M.

Based on Virtus ETF Advisers's 13F filing for Q1 2021, filed 17 May 2021.